Nevro Corp ( (NVRO) ) just unveiled an announcement.
Nevro Corp. reported a better-than-expected worldwide revenue and adjusted EBITDA for Q3 2024, despite a 6.7% decline in overall revenue due to challenges in the U.S. spinal cord stimulation market and global pressures. The company is optimistic about its innovative AI-driven pain relief technology, HFX AdaptivAI, and its strategic growth initiatives, including new market releases and regulatory approvals in Europe. Nevro continues to adjust its financial guidance, maintaining focus on growth and diversification to enhance shareholder value.
For an in-depth examination of NVRO stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- Deutsche Bank Pounds the Table on Tesla Stock
- ‘Breath of Fresh Air,’ Says Daniel Ives About Rivian Stock
- ‘It’s Not Too Late to Load Up,’ Says Analyst About Nvidia Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
